| Literature DB >> 29696001 |
Ayse Z Sahan1, Tapas K Hazra2, Soumita Das1.
Abstract
Pathogenic and commensal microbes induce various levels of inflammation and metabolic disease in the host. Inflammation caused by infection leads to increased production of reactive oxygen species (ROS) and subsequent oxidative DNA damage. These in turn cause further inflammation and exacerbation of DNA damage, and pose a risk for cancer development. Helicobacter pylori-mediated inflammation has been implicated in gastric cancer in many previously established studies, and Fusobacterium nucleatum presence has been observed with greater intensity in colorectal cancer patients. Despite ambiguity in the exact mechanism, infection-mediated inflammation may have a link to cancer development through an accumulation of potentially mutagenic DNA damage in surrounding cells. The multiple DNA repair pathways such as base excision, nucleotide excision, and mismatch repair that are employed by cells are vital in the abatement of accumulated mutations that can lead to carcinogenesis. For this reason, understanding the role of DNA repair as an important cellular mechanism in combatting the development of cancer will be essential to characterizing the effect of infection on DNA repair proteins and to identifying early cancer biomarkers that may be targeted for cancer therapies and treatments.Entities:
Keywords: DNA damage; Fusobacterium nucleatum; Helicobacter pylori; bacterial infection; commensal bacteria; inflammation and cancer
Year: 2018 PMID: 29696001 PMCID: PMC5904280 DOI: 10.3389/fmicb.2018.00663
Source DB: PubMed Journal: Front Microbiol ISSN: 1664-302X Impact factor: 5.640
A compilation of bacteria, virus, and parasite-associated cancers with some of the available information on their link to BER, NER, and MMR protein expression or mutations.
| Bacteria-associated cancers | Gastric cancer | |||
| BER | NER | MMR | ||
| APE1 (Ding et al., | MSH2 and MLH1 (Kim et al., | |||
| MLH1, MSH2, MSH3, and MSH6 (Santos et al., | ||||
| Colon cancer | Enteropathogenic | |||
| BER | NER | MMR | ||
| MSH2 and MLH1 (Maddocks et al., | ||||
| BER | NER | MMR | ||
| BER | NER | MMR | ||
| Lung cancer | ||||
| BER | NER | MMR | ||
| BER | NER | MMR | ||
| Bladder cancer | ||||
| BER | NER | MMR | ||
| 8-oxo-dG (Salim et al., | ||||
| APE1 (Salim et al., | ||||
| Ovarian cancer | ||||
| BER | NER | MMR | ||
| BER | NER | MMR | ||
| Virus-associated cancers | Cervical cancer | Human Papilloma Virus (HPV) (Bosch et al., | ||
| BER | NER | MMR | ||
| XRCC1 (Bajpai et al., | ERCC2 (Bajpai et al., | hMLH1 (Ciavattini et al., | ||
| APE-1 (Shekari et al., | ERCC4 (Bajpai et al., | hMSH2 (Ciavattini et al., | ||
| ERCC5(Joo et al., | hMLH3 (Ye et al., | |||
| Head and neck (Oropharyngeal) Squamous cell cancer | Human Papilloma Virus (HPV) (Hajek et al., | |||
| BER | NER | MMR | ||
| XRCC1 (Nickson et al., | ATR (Maddocks et al., | |||
| DNA polymerase β (Nickson et al., | ERCC1 (Langer, | |||
| PNKP (Nickson et al., | ||||
| PARP-1 (Nickson et al., | ||||
| Hepatocellular Carcinoma | Hepatitis B Virus (HBV) (El-Serag, | |||
| BER | NER | MMR | ||
| XRCC1 (Almeida Pereira Leite et al., | TFIIH (Arbuthnot and Kew, | |||
| OGG1 (Bose et al., | TFIIB (Arbuthnot and Kew, | |||
| TDG (van de Klundert et al., | XPB (Jia et al., | |||
| XPD (Jia et al., | ||||
| XAP-1 (DDB1) (Sohn et al., | ||||
| Hepatitis C Virus (HCV) (El-Serag, | ||||
| BER | NER | MMR | ||
| Neil1 (Higgs et al., | XPD (Gulnaz et al., | hMSH2 (Helal et al., | ||
| XRCC1 (Gulnaz et al., | hMLH1 (Helal et al., | |||
| XRCC3 (Gulnaz et al., | ||||
| Nasopharyngeal Cancer | Epstein-Barr Virus (EBV) (Huang et al., | |||
| BER | NER | MMR | ||
| XPA (Fu et al., | ||||
| T Cell leukemia | Human T Lymphotropic Virus Type I (HTLV-1) (Liao, | |||
| BER | NER | MMR | ||
| XRCC5 (Ng et al., | ERCC5 (Ng et al., | |||
| Kaposi sarcoma | Kaposi sarcoma-associated Herpes Virus (KSHV or HHV8) (Liao, | |||
| BER | NER | MMR | ||
| APE1 (Zhong et al., | ||||
| UNG2 (Verma et al., | ||||
| Parasite-associated cancer | Urinary bladder cancer | |||
| BER | NER | MMR | ||
| Cholangio carcinoma | ||||
| BER | NER | MMR | ||
| hMSH2 (Liengswangwong et al., | ||||
| hMLH1 (Liengswangwong et al., | ||||
There are many gaps in knowledge in this field, particularly in the field of bacteria-associated cancers and regulation of various DNA repair pathway proteins.
Figure 1DNA damage response and the potential role of ROS in inhibition of DNA repair. DNA damage is induced by external (various environmental pollutants, chemicals, and radiation), and internal resources (infection, cellular metabolism and replication errors). These DNA damages affect the cell cycle check point, apoptosis, transcriptional activation and cancer. Part of the DNA damages (DNA base adducts, mismatch bases, damaged bases, and double strand breaks) are repaired by the nucleotide excision repair, mismatch repair, base excision repair, and homologous recombination (HR) and non-homologous end joining (NHEJ) pathways, respectively. Many of the DNA damages are ROS-induced and recognized by the BER pathway which excises and repairs the lesions. However, ROS may potentially inhibit repair through down-regulation of certain initial proteins in the BER pathway, which can cause a buildup of carcinogenic mutations and ultimately lead to tumor progression.
Figure 2Immune response to bacterial infection. Once a bacterial infection is recognized by PRRs on host cells as part of the innate immune response, inflammatory cytokines and chemokines are released to draw neutrophils to the site of infection. Neutrophils phagocytose and kill the bacteria with ROS. If this initial response does not kill the bacteria, the adaptive immune response kicks in and may result in a chronic inflammatory response.
Figure 3ROS flowchart. ROS produced by either exogenous sources, such as radiation, or endogenous sources, such as through cellular mitochondria, can induce DNA damage through oxidation or cause post-translational modifications on cellular proteins.